Clinical trials: Flu
Seasonal Influenza Vaccine
Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects
- Trial name
- NCT00511914
- Testing
- cTIV
- Where
- 2 sites in Germany
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants
The primary aim is to define the immune responses to the infant's initial influenza exposure (vaccine or infection) and how that affects the immune response to subsequent influenza exposures
- Trial name
- NCT05436184
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Influenza Immunization
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.
- Trial name
- Vakzimeter FLU (NCT06800885)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
The Benefit and Harm of Fever Suppression by Antipyretics in Influenza
The purpose of this study is to investigate the potential benefits and risks of antipyretics use in naturally occurring influenza virus infections in humans.
- Trial name
- NCT01891084
- Testing
- Paracetamol, Backup NSAID ibuprofen
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human
A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
This study is a pediatric dose-ranging study to evaluate the safety and immunogenicity of vaccination with different MF59-adjuvanted H5N1 vaccine formulations.
- Trial name
- NCT04669691
- Testing
- H5N1 antigen combined with MF59 adjuvant
- Where
- 7 sites in Estonia, Philippines
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Swine-origin A/H1N1 Influenza
A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956202
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Selenium Supplementation, Influenza Vaccination
Effect of Selenium Supplementation on Influenza Vaccination
The study is designed to assess whether selenium supplementation can boost the immunity response to influenza vaccination in healthy adults.
- Trial name
- NCT04188483
- Testing
- Selenium Supplementation, Influenza vaccination
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Influenza (Healthy Volunteers)
Evaluating Modes of Influenza Transmission 2b Baseline SAR
This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy "Recipient" in this study involves: Home semi-quarantine lasting about 14 days during which the participants must…
- Trial name
- EMIT-2b-1 (NCT07342556)
- Testing
- Exposure to Donors with naturally acquired influenza virus infection
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Influenza
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to characterize the immunogenicity and safety of 3 doses of GSK's avian flu vaccine GSK 1557484A given at different time intervals to adults aged 18 years or greater who are at increased occupational…
- Trial name
- NCT01045564
- Testing
- GSK influenza virus H5N1 vaccine 1557484A
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years.
- Trial name
- NCT02212106
- Testing
- bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
- Where
- 11 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
Immune Response
Immune Responses Induced by Different Licensed Influenza Vaccines
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
- Trial name
- NCT00902278
- Testing
- Flulaval, Fluvirin, Fluzone
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Vaccine Response Impaired
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody…
- Trial name
- ARIVA (NCT04059991)
- Testing
- Influenza Vaccination
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Human Influenza
Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine
The study is Multicenter, phase 3, Open-Label trial that explored the preventive effectiveness, safety and immunogenicity of single dose a allantoic split inactivated seasonal influenza vaccine in healthy adults.
- Trial name
- NCT03572491
- Testing
- influenza vaccine
- Where
- Kazakhstan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
Influenza Vaccine Allergy, Cell Mediated Reaction
Immune Response Study of Influenza Vaccine
An observational clinical study will be performed in subjects aged 12-60 years old to describe the dynamic changes of humoral immune/cellular immunity after vaccination of influenza vaccine, and to discuss the role of different…
- Trial name
- NCT01310374
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Seasonal Influenza
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
The purpose of this study is to evaluate the safety and immunogenicity of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotech Co., Ltd.
- Trial name
- NCT05431725
- Testing
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Control Quadrivalent influenza virus vaccine
- Where
- 11 sites in Chile, Philippines
- Volunteers
- 2,202 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza, Influenza Immunisation
Flublok or Fluzone With Advax-CpG55.2 or AF03
This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03945825
- Testing
- AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 8 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
The purpose of this Phase 1/2 study is to generate sufficient safety and immunogenicity data of mRNA-1018 pandemic influenza candidate vaccines in healthy adults ≥18 years of age to enable the initiation of a large Phase 3 trial…
- Trial name
- NCT05972174
- Testing
- mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern Hemisphere (NH) 2015 2016 seasonal…
- Trial name
- NCT02550197
- Testing
- Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016, Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
- Where
- 5 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.